Mengke Pharmaceutical: Net loss attributable to the parent company of 242 million yuan in 2025

K-LinePoet · 2026-03-19T01:48:42+00:00

Mengke Pharmaceutical released its performance quick report. In 2025, it achieved total operating revenue of 142 million yuan, representing a year-on-year increase of 8.83%; net profit attributable to owners of the parent company of -242 million yuan, a year-on-year decrease in losses of 199 million yuan; net profit attributable to owners of the parent company after deducting non-recurring gains and losses of -250 million yuan, a year-on-year decrease in losses of 209 million yuan.

K-LinePoet

2026-03-19 01:48:42

Mengke Pharmaceutical releases a quick report on its performance. In 2025, it achieved a total revenue of 142 million yuan, an increase of 8.83% year-over-year; net profit attributable to the parent company was -242 million yuan, a decrease in loss of 199 million yuan compared to the previous year; net profit attributable to the parent company after deducting non-recurring gains and losses was -250 million yuan, a decrease in loss of 209 million yuan year-over-year.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes